Last updated: October 23, 2026
Our Mission
ABXMedX is an independent educational website about three different prescription antibiotic groups in the United States: azithromycin, doxycycline and sulfamethoxazole/trimethoprim (TMP-SMX), often recognized by the Bactrim brand. We explain product labels, brand and generic distinctions, legitimate prescription access, clinical safety concerns and the limits of antibiotic comparisons. ABXMedX does not diagnose disease, write prescriptions, dispense medications or guarantee treatment outcomes.
A person searching for Zithromax, an Oracea capsule or a Bactrim DS tablet may encounter the word “antibiotic” on all three product records. That shared category does not make the medicines interchangeable. Each has different approved forms, spectra of activity, warnings and clinical uses. We organize topics around those distinctions rather than encourage readers to choose an antibiotic based on a price or search result.
What ABXMedX Covers
Our azithromycin hub explains macrolide products, Zithromax and Z-Pak terminology, oral tablets and suspension, QT-related precautions and prescription-access questions. Our doxycycline hub distinguishes hyclate from monohydrate, capsules from tablets, and ordinary antimicrobial products from specialized formulations such as Doryx MPC and Oracea 40 mg. Our Bactrim hub covers the two-component TMP-SMX combination, regular and double-strength presentations, generic labeling and significant interaction and allergy concerns.
Additional pages discuss pharmacy verification, legitimate online prescribing, brand-to-generic evidence, commercial price factors and comparisons with other antibiotics. Prices and insurance terms are deliberately discussed without claiming a fixed national amount or live inventory. We do not represent historical drug-brand records as proof that a discontinued product is currently sold.
Which Evidence Answers Which Question
Product approval, NDC listing, prescribing instructions and clinical treatment recommendations are separate evidence categories. The FDA Orange Book is useful for approved product records and therapeutic-equivalence evaluations. FDA NDC guidance explains why a labeler-submitted code is not itself proof of approval. DailyMed publishes product-specific prescribing information, but readers must identify the exact formulation and labeler.
Condition-specific decisions need clinical guidance as well as drug labels. For example, CDC chlamydia guidance explains where doxycycline and azithromycin differ in recommended treatment. CDC Rocky Mountain spotted fever guidance highlights an important pediatric exception in doxycycline prescribing. IDSA skin-infection guidance distinguishes purulent abscesses from nonpurulent cellulitis when discussing potentially MRSA-active drugs.
| Source | Useful for | Not evidence of |
|---|---|---|
| FDA Orange Book | Approval and evaluated therapeutic equivalence | A specific pharmacy having stock |
| FDA NDC Directory | Submitted package and labeler identification | FDA approval by itself |
| DailyMed label | Strength, dosage form, warnings and labeled indications | An individual patient’s correct treatment |
| CDC and IDSA guidance | Diagnosis- and population-specific recommendations | An antibiotic being suitable for every symptom |
| Licensed pharmacy | A verified quote and actual dispensing options | A diagnosis or prescription authorization |
Our Approach to Comparisons and Independence
ABXMedX distinguishes generic substitution within an approved drug product family from a clinical choice between different active ingredients. An azithromycin tablet cannot fill a doxycycline prescription, and neither can automatically substitute for a TMP-SMX combination. Even within a single antibiotic, delayed-release designs, salts, oral liquids and tablet strengths may require different assessments.
Some articles may link to independent businesses through clearly disclosed sponsored or affiliate referrals. Such a relationship does not certify pharmacy licensing, safety, prescription approval, current stock or an effective treatment for any reader. We separate commercial referrals from the medical and regulatory basis of an article.
Corrections, Medical Review and Reader Responsibilities
We prioritize correcting wrong drug strengths, misleading marketing-status claims, outdated sources, inaccurate interaction information and anything that could prompt unsafe antibiotic substitution. Our Editorial Policy describes sources and corrections. Our Medical Review Process and Reviewer Standards explain why an editorial check is not the same as a documented clinical review by an identified professional.
Report a concrete error through Contact ABXMedX, with the page URL and a public source where possible. Please do not send prescriptions, patient identifiers, medical histories or payment information. Medical symptoms and individual treatment decisions belong to a licensed clinician or pharmacist; emergencies require immediate appropriate care.